Online Inquiry
Onvansertib (NMS-P937)
SPC-01558
CAS No. 1034616-18-6
| Size | Price |
| 10 mg | Online Inquiry |
| Bulk Size | Online Inquiry |
PLK inhibitor ; Apoptosis related activator
| Description |
|---|
| Onvansertib (NMS-P937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Onvansertib (NMS-P937) potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits tumor growth. Phase 1. |
| Product Details | |
|---|---|
| CAS No. | CAS No. 1034616-18-6 |
| Description | Onvansertib (NMS-P937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Onvansertib (NMS-P937) potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits tumor growth. Phase 1. |
| Formula | C24H27F3N8O3 |
| Molecular Weight | 532.52 |
| Storage | 3 years -20°C powder 2 years -80°C in solvent |
| Synonyms | PCM-075, NMS1286937 |
| SMILES | CN1CCN(CC1)C2=CC(=C(C=C2)OC(F)(F)F)NC3=NC=C4CCC5=C(C4=N3)N(N=C5C(=O)N)CCO |
| Usage | |
|---|---|
| Storage | 3 years -20°C powder 2 years -80°C in solvent |
For research use only. Not intended for any clinical use. No products from CD BioSciences may be resold, modified for resale or used to manufacture commercial products without prior written approval from CD BioSciences.